Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar portefeuille (99.75) Submitted: 3/13/2011 4:59:24 PM : Outperform Start Price: $1.48 DYAX Score: +13.92

see this post.
http://caps.fool.com/Blogs/dyax/556162.

Featured Broker Partners


Advertisement